77 related articles for article (PubMed ID: 16202261)
21. Large B-cell lymphoma with Hodgkin's features.
García JF; Mollejo M; Fraga M; Forteza J; Muniesa JA; Pérez-Guillermo M; Pérez-Seoane C; Rivera T; Ortega P; Piris MA
Histopathology; 2005 Jul; 47(1):101-10. PubMed ID: 15982329
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
Pedersen LM; Jürgensen GW; Johnsen HE
Br J Haematol; 2005 Mar; 128(6):813-9. PubMed ID: 15755285
[TBL] [Abstract][Full Text] [Related]
23. [Primary diffuse large B-cell lymphoma of testis: a clinicopathologic study of 14 cases].
Li D; Mi C; Zhao Y; Wang YL; Ma Y; Li YY; Xiang MH
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):461-5. PubMed ID: 17845759
[TBL] [Abstract][Full Text] [Related]
24. [Clinical characteristics, cell origin and prognosis of primary gastrointestinal diffuse large B-cell lymphoma: a report of 40 cases].
Yang YL; Wang J; Zhao LZ; Gao ZF; Jing HM; Ke XY
Ai Zheng; 2008 Jun; 27(6):636-41. PubMed ID: 18570740
[TBL] [Abstract][Full Text] [Related]
25. CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses.
Biasoli I; Morais JC; Scheliga A; Milito CB; Romano S; Land M; Pulcheri W; Spector N
Histopathology; 2005 Mar; 46(3):328-33. PubMed ID: 15720419
[TBL] [Abstract][Full Text] [Related]
26. Mad2 overexpression is associated with high cell proliferation and reduced disease-free survival in primary gastrointestinal diffuse large B-cell lymphoma.
Chen F; Liu S; Zhou Y; Shen H; Zuo X
Hematology; 2016 Aug; 21(7):399-403. PubMed ID: 27077767
[TBL] [Abstract][Full Text] [Related]
27. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
Obermann EC; Csato M; Dirnhofer S; Tzankov A
J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
[TBL] [Abstract][Full Text] [Related]
28. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994
[TBL] [Abstract][Full Text] [Related]
29. [The clinical characteristics and prognostic analysis of 147 cases of diffuse large B-cell lymphoma].
Zhao Q; Fu WJ; Zhang CY; Du J; Xi H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2013 Sep; 34(9):737-40. PubMed ID: 24103868
[TBL] [Abstract][Full Text] [Related]
30. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab.
Gaudio F; Giordano A; Perrone T; Pastore D; Curci P; Delia M; Napoli A; de' Risi C; Spina A; Ricco R; Liso V; Specchia G
Acta Haematol; 2011; 126(1):44-51. PubMed ID: 21430371
[TBL] [Abstract][Full Text] [Related]
31. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas.
Zhang A; Ohshima K; Sato K; Kanda M; Suzumiya J; Shimazaki K; Kawasaki C; Kikuchi M
Pathol Int; 1999 Dec; 49(12):1043-52. PubMed ID: 10632924
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological and prognostic significance of p53, Ki-67, and Bcl-2 expression in Tunisian gastric adenocarcinomas.
Ayed DB; Khabir A; Abid M; Bayrouti MI; Gargouri A; Sellami-Boudawara T; Mokdad-Gargouri R
Acta Histochem; 2014 Oct; 116(8):1244-50. PubMed ID: 25095748
[TBL] [Abstract][Full Text] [Related]
33. p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
Xie Y; Bulbul MA; Ji L; Inouye CM; Groshen SG; Tulpule A; O'Malley DP; Wang E; Siddiqi IN
Am J Clin Pathol; 2014 Apr; 141(4):593-604. PubMed ID: 24619762
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
[TBL] [Abstract][Full Text] [Related]
35. A clinicopathologic and immunohistochemical study of diffuse large B-cell lymphoma.
Tao K; Zhu X; Xu W; Chen Z; Lu H
Zhonghua Bing Li Xue Za Zhi; 2002 Apr; 31(2):112-5. PubMed ID: 12419155
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical investigation of P16, P53 and Ki-67's prognostic values in diffuse large B-Cell lymphomas.
Baran M; Canoz O; Altuntas H; Sivgin S; Cetin M; Yay A; Ketenci S
Bratisl Lek Listy; 2017; 118(10):602-608. PubMed ID: 29198127
[TBL] [Abstract][Full Text] [Related]
37. CD56-positive diffuse large B-cell lymphoma: possible association with extranodal involvement and bcl-6 expression.
Gomyo H; Kajimoto K; Miyata Y; Maeda A; Mizuno I; Yamamoto K; Obayashi C; Hanioka K; Murayama T
Hematology; 2010 Jun; 15(3):157-61. PubMed ID: 20557674
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time.
Chang ST; Lu YH; Lu CL; Weng SF; Lin SH; Kuo SY; Chuang YT; Takeuchi K; Ohshima K; Chuang SS
J Clin Pathol; 2014 Apr; 67(4):326-32. PubMed ID: 24218026
[TBL] [Abstract][Full Text] [Related]
39. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
40. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]